These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Science and the law. Working through the patent problem. Walsh JP; Cohen WM; Arora A Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928 [No Abstract] [Full Text] [Related]
10. Enzo Biochem v. Gen-Probe: complying with the written description requirement under US patent law. Blaug S; Shuster M; Su H Nat Biotechnol; 2003 Jan; 21(1):97-9. PubMed ID: 12511910 [No Abstract] [Full Text] [Related]
11. Research tool patents: tips for facing a "pay up now or litigate" ultimatum. Gogoris A; Ancona P Nat Biotechnol; 2001 Nov; 19(11):1075-7. PubMed ID: 11689855 [No Abstract] [Full Text] [Related]
12. Amgen protects its billion dollar protein. Chahine K Nat Biotechnol; 1997 Jun; 15(6):496-7. PubMed ID: 9181560 [No Abstract] [Full Text] [Related]
14. Landscape of chromatin control element patents: positioning effects in pharmaceutical bioproduction. Palazzoli F; Bire S; Bigot Y; Bonnin-Rouleux F Nat Biotechnol; 2011 Jul; 29(7):593-7. PubMed ID: 21747382 [No Abstract] [Full Text] [Related]
15. Will pharmacogenomics alter the role of patents in drug development? Eisenberg RS Pharmacogenomics; 2002 Sep; 3(5):571-4. PubMed ID: 12223043 [No Abstract] [Full Text] [Related]
16. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney. Melethil S AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948 [TBL] [Abstract][Full Text] [Related]
17. Post-patent barriers to entry in the pharmaceutical industry. Scherer FM J Health Econ; 1985 Mar; 4(1):83-7. PubMed ID: 10271148 [No Abstract] [Full Text] [Related]
18. Researcher and Amgen baffled by love letter. Dove A Nat Biotechnol; 1998 Jun; 16(6):511. PubMed ID: 9624673 [No Abstract] [Full Text] [Related]
19. Amgen battles for EPO in Congress. Chahine K Nat Biotechnol; 1998 Nov; 16(11):999-1000. PubMed ID: 9831016 [No Abstract] [Full Text] [Related]